- Global Pharma News & Resources

SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors

  • Majority of patients receiving SOT101 (SO-C101) + pembrolizumab had confirmed clinical benefit
  • Clinical responses have been observed in patients progressing on previous anti-PD-1 treatment
  • SOT101 monotherapy and in combination with pembrolizumab was well tolerated in patients with advanced/metastatic solid tumors

BASEL, Switzerland, November 12, 2021 / B3C newswire / -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced new data from the ongoing Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, as a monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors. The data are presented in three posters at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting from November 10-14, 2021.

In a combination of SOT101 with pembrolizumab in the AURELIO-03 study, the majority of the 13 patients with advanced/metastatic solid tumors had clinical benefit, including in checkpoint inhibitor (CPI) refractory patients. In this dose escalation study, investigators to date have observed three confirmed partial responses and four instances of long-lasting stable disease. These patients had a median of two lines of prior therapy (range 1-6). In addition, SOT101 in combination with pembrolizumab was generally well tolerated. Dose escalation in this study is ongoing.

A SOT101 monotherapy arm of the study demonstrated encouraging efficacy signals in the 30 patients with advanced/metastatic solid tumors, including in CPI refractory patients. To date, there has been one confirmed clinical and radiological response and confirmed stable disease in four patients. Additionally, one patient had a partial response on SOT101+pembrolizumab combination therapy after experiencing a relapse on SOC101 monotherapy. SOT101 was well tolerated, and the majority of treatment emergent adverse events were Grade 2 or less. Patients in this dose escalation study have had a median of three lines of prior therapy (range 1-9). The recommended Phase 2 dose has been defined at 12 μg/kg and a Phase 2 monotherapy expansion study at this dose is ongoing in selected tumor indications.

An analysis of biomarkers in the study shows that SOT101 activates both the innate and adaptive immunity. Key data show that SOT101 induced a robust immune-stimulatory response in various types of tumor microenvironments. Investigators observed a dose-dependent pharmacodynamic response in the blood of all patients in the monotherapy and SOT101+pembrolizumab arms, and clinically responsive patients showed increased CD8+ T cell and NK cell infiltration in the tumor. Furthermore, SOT101 restored the sensitivity to CPIs in CPI refractory/resistant patients.

“These results represent a promising clinical path forward for SOTIO as they highlighted the strong safety and promising efficacy to date of SOT101 alone and in combination with pembrolizumab and have defined the recommended Phase 2 dose for SOT101,” said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. “We are encouraged by the clinical responses we have observed in patients with advanced solid tumors. We look forward to continuing development of SOT101 with further follow up of this study, the continuation of the ongoing Phase 2 SOT101 monotherapy study, and the initiation of a Phase 2 combination study, during the next year.”

Aurélien Marabelle, M.D., Ph.D., Immuno-Oncologist from the Drug Development Department at Gustave Roussy Cancer Center and principal investigator on the Phase 1/1b trial, added, “While the industry has made significant progress in providing novel cancer treatments in the last decade, we are still in desperate need of new therapeutic options for patients with cancer. The data presented at this year’s SITC underscore the potential of SOT101 to have a true impact on the treatment of advanced or metastatic solid tumors.” 

All poster presentations are available on the SOTIO Biotech website.


About SOT101
SOT101 (SO-C101) is a subcutaneously-administered IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor α chain. SOT101 has demonstrated strong preclinical in vivo efficacy in various tumor models showing increased long-term survival and tumor regression, as well as a favorable toxicology profile. SOT101 has been shown in pre-clinical models to synergize with checkpoint inhibitors and antibody therapies exerting ADCC.

About SOTIO Biotech
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. The robust SOTIO clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, SOT101, currently being tested phase II clinical trials. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, an IL-15-based immunocytokine, BOXR1030, a GPC3 targeted CAR-T based on proprietary technology designed to improve on the efficacy of CAR-T therapies in the tumor microenvironment and SOT102, a next generation Claudin18.2 targeted antibody-drug conjugate (ADC). SOTIO is a member of the PPF Group.
SOTIO is a registered trademark of SOTIO Biotech a.s. in selected countries.



SOTIO Biotech 
Richard Kapsa
Head of Communication
T: (+420) 224 174 448
M: (+420) 603 280 971

Media contact

LifeSci Communications
Michael Tattory
+1 609-802-6265


Keywords: Humans; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Medical Oncology; IL15 protein, human; Interleukin-15; Receptors, Interleukin-15; Melanoma; Neoplasms; Tumor Microenvironment; Immunotherapy; pembrolizumab; Immunoconjugates; Antibodies, Monoclonal, Humanized; Immunologic Factors; Killer Cells; CD8-Positive T-Lymphocytes; T-Lymphocytes; Adaptive Immunity; Immunity, Innate


Published by B3C newswire

Editor Details

Last Updated: 17-Nov-2021